3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
36
KEQU Quote, Financials, Valuation and Earnings
Last price:
$38.69
Seasonality move
:
2.37%
Day range:
$38.00 - $40.15
52-week range:
$30.82 - $71.33
Dividend yield:
0%
P/E ratio:
6.66x
P/S ratio:
0.53x
P/B ratio:
1.85x
Volume:
125.4K
Avg. volume:
29.9K
1-year change:
14.48%
Market cap:
$112.4M
Revenue:
$203.8M
EPS (TTM):
$5.91
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Kewaunee Scientific has -28.9% downside to fair value with a price target of -- per share.
KEQU vs. S&P 500
-
Over the past 5 trading days, Kewaunee Scientific has underperformed the S&P 500 by -10.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kewaunee Scientific does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kewaunee Scientific has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Kewaunee Scientific reported revenues of $67.2M.
Earnings Growth
-
Kewaunee Scientific earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Kewaunee Scientific reported earnings per share of $0.45.
Enterprise value:
143.4M
EV / Invested capital:
1.42x
Price / LTM sales:
0.53x
EV / EBIT:
12.34x
EV / Revenue:
0.65x
PEG ratio (5yr expected):
0.07x
EV / Free cash flow:
36.84x
Price / Operating cash flow:
30.12x
Enterprise value / EBITDA:
9.18x
Gross Profit (TTM):
$59.5M
Return On Assets:
12.27%
Net Income Margin (TTM):
7.99%
Return On Equity:
31.19%
Return On Invested Capital:
26.51%
Operating Margin:
3.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $215.2M | $201M | $220M | $46.8M | $67.2M | |
| Gross Profit | $34.6M | $47.8M | $59.5M | $12M | $18.4M | |
| Operating Income | $4.9M | $15.4M | $10.6M | $3.8M | $2.3M | |
| EBITDA | $8.8M | $18.9M | $15.6M | $4.7M | $4M | |
| Diluted EPS | -$0.24 | $2.98 | $5.91 | $0.85 | $0.45 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $60.1M | $68.9M | $91.6M | $96.2M | $108.6M | |
| Total Assets | $89.6M | $95.7M | $121.8M | $126.3M | $189.1M | |
| Current Liabilities | $31.6M | $47.5M | $44.2M | $42.1M | $50.2M | |
| Total Liabilities | $51.3M | $59.5M | $85.4M | $81M | $127M | |
| Total Equity | $38.3M | $36.2M | $36.3M | $45.3M | $62.1M | |
| Total Debt | $4.5M | $9M | $5.8M | $3.2M | $39.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.3M | $18.2M | $6.5M | $9.5M | -$2.3M | |
| Cash From Investing | -$2.2M | -$6M | -$31.4M | -$475K | -$29.4M | |
| Cash From Financing | $26M | -$3.7M | $10.3M | -$3.6M | $14.6M | |
| Free Cash Flow | -$12.6M | $12.2M | $3.9M | $9M | -$3M | |
KEQU
Sector
Market Cap
$112.4M
$37M
Price % of 52-Week High
55.21%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
14.48%
-43.58%
Beta (5-Year)
0.595
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$42.91
200-day SMA
Sell
Level
$47.11
Bollinger Bands (100)
Sell
Level
41.59 - 61.45
Chaikin Money Flow
Buy
Level
489.9K
20-day SMA
Sell
Level
$46.98
Relative Strength Index (RSI14)
Sell
Level
30.91
ADX Line
Sell
Level
31.14
Williams %R
Buy
Level
-90.7943
50-day SMA
Sell
Level
$55.61
MACD (12, 26)
Sell
Level
-4.25
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
3.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.6439)
Buy
CA Score
(Annual)
Level (0.0692)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (0.1937)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
Stock Forecast FAQ
In the current month, KEQU has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KEQU average analyst price target in the past 3 months is --.
-
Where Will Kewaunee Scientific Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kewaunee Scientific share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Kewaunee Scientific?
Analysts are divided on their view about Kewaunee Scientific share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kewaunee Scientific is a Sell and believe this share price will rise from its current level to --.
-
What Is Kewaunee Scientific's Price Target?
The price target for Kewaunee Scientific over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KEQU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kewaunee Scientific is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of KEQU?
You can purchase shares of Kewaunee Scientific via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kewaunee Scientific shares.
-
What Is The Kewaunee Scientific Share Price Today?
Kewaunee Scientific was last trading at $38.69 per share. This represents the most recent stock quote for Kewaunee Scientific. Yesterday, Kewaunee Scientific closed at $39.38 per share.
-
How To Buy Kewaunee Scientific Stock Online?
In order to purchase Kewaunee Scientific stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 17.78% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 6.75% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 5.9% over the past day.
